Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

World AIDS Day: Make it happen (Patent Baristas) (IP Watch)

Venezuela to examine all pharmaceutical patents (IP tango)

World AIDS Day: Make it happen (Patent Baristas) (IP Watch)

Biodiversity negotiations need to allow for flexibility in business, industry says (IP Watch)

Brazilian government tailors a bill on trade sanctions (IP tango)

Kenya: Pharmaceutical patent pools seen as a life and death matter in Kenya (IP Watch)

Peru: Instructing your society: how to avoid illegal medicines (IP tango)

US: BRCA gene patents lawsuit lives on (IP Osgoode)

US: Amicus briefs in Ariad v Lilly (Patent Docs) (Patent Docs) (Patent Docs)

US: Follow-on biologics news briefs – no. 10 (Patent Docs)

Venezuela to examine all pharmaceutical patents (IP tango)

Alphagan (Brimonidine) – US: Exela files appeal to District Court Delaware’s decision finding patent infringement (Patent Docs)

Cosopt (Timolol, Dorzolamide) –UK: Inventive step: another nuance: Teva UK Ltd v Merck & Co Inc (PatLit) (IPKat)

Cutivate (Fluticasone) – US: Nycomed files patent infringement suit against Perrigo following Para IV challenge (Patent Docs)

Ebixa (Memantine) – Canada: Patent Act (post 1996) imposes duty of candour and good faith; Lundbeck’s patent invalidated: Lundbeck Canada Inc et al v Ratiopharm Inc (Patent Baristas)

Evoxac (Cevimeline) – US: Daiichi Sankyo files patent infringement suit in response to Sandoz’ ANDA to manufacture generic Evoxac (Patent Docs)

Famvir (Famciclovir) – US: Novartis prevails over Teva in Famvir suit (Patent Docs)

Lipitor (Atorvastatin) – Philippines: Why are drug expensive in the US? Because other countries just decide to pay less – Pfizer’s patent battle against UniLab (Patent Baristas)

Moxifloxacin – Venezuela annuls two of Bayer’s patents relating to Moxifloxacin (IP tango) (IP tango)

Plavix (Clopidogrel) – India: Indian company, Cadila, bears the brunt of section 3(d) (Spicy IP)

Sanctura (Trospium) – US: Allergan files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Taxotere (Docetaxel) – Canada: Disclaimers can be validly filed after receipt of a NOA: Sanofi-Aventis Canada Inc v Hospira Healthcare Corporation (Patent Baristas)

Vigamox (Moxifloxacin) – US: Teva announces intent to appeal ruling that it infringed Alcon’s Vigamox patent (Patent Docs)

Yaz (Drospirenone, Ethinyl estradiol) – Canada: Formulation patents must claim all medicinal ingredients; Bayer’s patent ineligible for listing on Patent Register: Bayer Inc v Canada (Minister of Health) et al (Patent Baristas)

Zemplar (Paricalcitol) – US: Abbott Laboratories, WARF file patent infringement suit against Teva following Para IV challenge (Patent Docs)